Psoriasis 2 - Current and future management of psoriasis

被引:255
作者
Menter, Alan
Griffiths, Christopher E. M. [1 ]
机构
[1] Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England
[2] Baylor Res Inst, Dallas, TX 75246 USA
[3] SW Med Sch, Dallas, TX 75246 USA
关键词
D O I
10.1016/S0140-6736(07)61129-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Management of psoriasis begins with identification of the extent of cutaneous disease. However, a holistic, contractual approach to treatment is encouraged, with particular reference to psychosocial disability and quality-of-life issues. of The presence of psoriasis on palms, soles, body folds, genitals, face, or nails, and concomitant joint disease, are also important when considering treatment options. An evidence-based approach is essential in delineating differences between the many available treatments. However, archaic approaches, especially combinational ones, are routinely used by some clinicians, with inadequate prospective or comparative evidence. Treatments currently available are: topical agents used predominantly for mild disease and for recalcitrant lesions in more severe disease; phototherapy for moderate disease; and systemic agents including photochemotherapy, oral agents, and newer injectable biological of agents, which have revolutionised the management of severe psoriasis. Other innovative treatments are undergoing clinical studies, with the aim of maintaining safe, long-term control of the condition.
引用
收藏
页码:272 / 284
页数:13
相关论文
共 145 条
  • [1] A novel liposomal formulation of dithranol for psoriasis: Preliminary results
    Agarwal, R
    Saraswat, A
    Kaur, I
    Katare, OP
    Kumar, B
    [J]. JOURNAL OF DERMATOLOGY, 2002, 29 (08) : 529 - 532
  • [2] [Anonymous], 2005, Prescrire Int, V14, P123
  • [3] Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    Antoni, C
    Krueger, GG
    de Vlam, K
    Birbara, C
    Beutler, A
    Guzzo, C
    Zhou, B
    Dooley, LT
    Kavanaugh, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1150 - 1157
  • [4] Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis
    Ashcroft, DM
    Po, ALW
    Williams, HC
    Griffiths, CEM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7240): : 963 - 967
  • [5] Bawle EV, 1998, TERATOLOGY, V57, P51, DOI 10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.0.CO
  • [6] 2-9
  • [7] A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis
    Bissonnette, R
    Papp, K
    Poulin, Y
    Lauzon, G
    Aspeslet, L
    Huizinga, R
    Mayo, P
    Foster, RT
    Yatscoff, RW
    Maksymowych, WP
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : 472 - 478
  • [8] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Bongartz, T
    Sutton, AJ
    Sweeting, MJ
    Buchan, I
    Matteson, EL
    Montori, V
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2275 - 2285
  • [9] Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: A pilot study
    Bowman, PH
    Maloney, JE
    Koo, JYM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (06) : 907 - 913
  • [10] Bruner Christine R, 2003, Dermatol Online J, V9, P2